Silibinin, an effective anti-
cancer and chemopreventive agent, has been shown to exert multiple effects on
cancer cells, including inhibition of both cell proliferation and migration. However, the molecular mechanisms responsible for these effects are not fully understood. We observed that
silibinin significantly induced the expression of the non-steroidal anti-inflammatory
drug-activated gene-1 (NAG-1) in both p53 wild-type and p53-null
cancer cell lines, suggesting that
silibinin-induced NAG-1 up-regulation is p53-independent manner.
Silibinin up-regulates early growth response-1 (EGR-1) expression. The ectopic expression of EGR-1 significantly increased NAG-1 promoter activity and NAG-1
protein expression in a dose-dependent manner. Furthermore, down-regulation of EGR-1 expression using
siRNA markedly reduced
silibinin-mediated NAG-1 expression, suggesting that the expression of EGR-1 is critical for
silibinin-induced NAG-1 expression. We also observed that
reactive oxygen species (ROS) are generated by
silibinin; however, ROS did not affect
silibinin-induced NAG-1 expression and apoptosis. In addition, we demonstrated that the
mitogen-activated protein kinase (MAP
kinase) signal transduction pathway is involved in
silibinin-induced NAG-1 expression. Inhibitors of
p38 MAP kinase (
SB203580) attenuated
silibinin-induced NAG-1 expression. Furthermore, we found that
siRNA-mediated knockdown of NAG-1 attenuated
silibinin-induced apoptosis. Collectively, the results of this study demonstrate for the first time that up-regulation of NAG-1 contributes to
silibinin-induced apoptosis in
cancer cells.